A N-acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic Index DOTA-Hapten Pretargeted Radioimmunotherapy.
暂无分享,去创建一个
S. Larson | N. Cheung | D. Veach | O. Ouerfelli | P. Zanzonico | S. Cheal | Mitesh Patel | Hong Xu | Hong-fen Guo | D. Axworthy | Guangbin Yang
[1] Michael M. Schmidt,et al. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.
[2] S. Larson,et al. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[3] P. Beaumier,et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] S. Larson,et al. Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy. , 2014, Molecular pharmaceutics.
[5] E. Yorke,et al. Use of normal tissue complication probability models in the clinic. , 2010, International journal of radiation oncology, biology, physics.
[6] J. Frangioni,et al. Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy , 2011, Molecular Imaging and Biology.
[7] Jason S. Lewis,et al. Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers. , 2018, Bioconjugate chemistry.
[8] P. Grewal,et al. The Ashwell-Morell receptor. , 2010, Methods in enzymology.
[9] M. Goris,et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] James G. Kereiakes,et al. An Introduction to the Physics of Diagnostic Radiology , 1972 .
[11] Steven M. Larson,et al. Radioimmunotherapy of human tumours , 2015, Nature Reviews Cancer.
[12] S. Larson,et al. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma , 2018, Theranostics.
[13] K Dane Wittrup,et al. Effect of Small-Molecule–Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody , 2012, Molecular Cancer Therapeutics.
[14] K Dane Wittrup,et al. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. , 2011, Nuclear medicine and biology.
[15] K Dane Wittrup,et al. A modular IgG-scFv bispecific antibody topology. , 2010, Protein engineering, design & selection : PEDS.
[16] K. Wittrup,et al. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. , 2018, Blood.
[17] S. Larson,et al. Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex , 2014, Molecular Cancer Therapeutics.
[18] K. Wittrup,et al. Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. , 2016, Cancer research.
[19] D. Fisher,et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. , 2000, Cancer biotherapy & radiopharmaceuticals.
[20] S. Larson,et al. N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein. , 2013, Bioconjugate chemistry.
[21] S. Larson,et al. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer , 2017, The Journal of Nuclear Medicine.